Research · updated weekly
Lose the weight. Keep everything else.
What was published, what kind of evidence it is, and whether it changes anything for you. Newest first.
Medically reviewed by Mark Nessim, MD, board-certified anesthesiologist · Last updated
Who publishes this: Habthera Nutrition, which makes ASP-1, a protein supplement. Where our product appears it is labeled as ours. Editorial policy.
How this page works
Each entry says what kind of evidence it is, what it found and what it changes for someone taking a GLP-1. A trial is stronger evidence than a records study, and a records study is stronger than a conference abstract or a small pilot, so we label every one. Newest first.
Week of November 16, 2026
Nov 10, 2026 · Randomized trial
What it found: In the T-REx trial, 120 adults aged 50 to 70 without diabetes took tirzepatide for 40 weeks, and half also did resistance training three times a week. Both groups lost about 22 kg. The training group lost 25% less lean tissue, and their upper and lower body strength rose about 10%, while strength in the group that didn't train fell about 10%.
What it means for you: Strong evidence that strength training changes what the weight loss is made of, even when the scale shows the same number. It reduced muscle loss but did not stop it, everyone was 50 to 70, and both groups also got protein advice. The trial used three sessions a week. What the trial means for you.
Source: Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial, Nature Medicine, 10 Nov 2026; University of Western Australia
Nov 14, 2026 · Records study (ObesityWeek; published in eClinicalMedicine)
What it found: Cleveland Clinic followed 20,486 patients who had used semaglutide or tirzepatide for at least three months. Over two years, average weight loss was about 11% for people who stayed on their original drug, about 16% for those who switched between semaglutide and tirzepatide, about 8% for those who switched to a different obesity medicine and about 4% for those who stopped with no further treatment. People who had bariatric surgery lost the most, more than a quarter of their body weight.
What it means for you: Stopping with no follow-up plan was linked to the smallest long-term result. Switching drugs may help if one stalls or isn't tolerated. This is health-record data, not a randomized trial, and people who switched or had surgery may differ in ways the study couldn't fully account for. If cost or side effects are pushing you to stop, talk with your prescriber about the options first.
Source: Cleveland Clinic newsroom, 14 Nov 2026; Healio
Nov 14, 2026 · Conference abstract (preliminary)
What it found: In 225,000 benefit checks for commercially insured adults in 2025, fewer than 4% showed coverage of semaglutide or tirzepatide for weight without a prior authorization. Of 69,462 prior authorization requests, 53.2% were approved and 35.7% were denied. About half of the denials (51.1%) were because the plan excludes or limits obesity drugs, and 24.7% because clinical criteria weren't met.
What it means for you: Ask why you were denied. A plan exclusion usually means the drug isn't a covered benefit, so a self-pay price may be the realistic route (current prices, telehealth costs compared). A denial for missing clinical criteria or a required earlier medication is worth asking your prescriber to resubmit or appeal with fuller records. Preliminary data from one telehealth platform, not yet peer reviewed.
Source: AJMC, ObesityWeek 2026 coverage, 14 Nov 2026 (late-breaking abstract, Broffman L, et al.)
Nov 14, 2026 · Conference abstract (preliminary)
What it found: Among 5,134 people who started semaglutide or tirzepatide for weight in 2024, the largest group stayed on low doses for the first six months: 45.1% of semaglutide users (averaging 0.9 mg a week) and 48.0% of tirzepatide users (averaging 5.5 mg). Only 25.1% and 12.7% followed something close to the labeled every-four-weeks increase.
What it means for you: Going slower than the label is common in real life. This study tracked doses and whether people kept taking the drug, not weight loss, so it can't tell you whether lower doses work as well. Dose changes are a decision for you and your prescriber. AJMC notes the analyses it covered from this session included coauthors affiliated with Amgen.
Source: AJMC, ObesityWeek 2026 coverage, 14 Nov 2026 (Chao AM, et al.)
Week of November 9, 2026
Nov 9, 2026 · FDA safety action
What it found: The FDA required all GLP-1 medicines, including semaglutide, tirzepatide and orforglipron, to warn about a possible increased risk of NAION, a rare cause of sudden vision loss. In 126 trials there were 10 probable cases on a GLP-1 and 5 on placebo.
What it means for you: Don't stop your medication over it. Know the symptom: sudden vision loss in one eye needs a same-day eye exam. Our full explainer.
Source: Pharmacy Times, 9 Nov 2026
Nov 9, 2026 · Records study (target trial emulation)
What it found: In JAMA Network Open, people with diabetes starting a GLP-1 had a lower risk of obesity-related cancers than those starting insulin, but not a lower risk than every other diabetes medicine.
What it means for you: Encouraging, but it compares medicines, not GLP-1 versus nothing, and it is in people with diabetes. It is not a reason to start a GLP-1 for cancer prevention.
Source: Medical Xpress; Hernández-Pérez JG et al., JAMA Netw Open 2026, doi:10.1001/jamanetworkopen.2026.41869
Nov 2026 · Small pilot study
What it found: In 38 adults without diabetes, three months of either drug was associated with about 7.2 kg of weight loss, fewer food cravings and more fullness. The two drugs did not differ.
What it means for you: Fits what many patients describe. With 38 people and no comparison group it is a starting point, not proof. Fewer cravings also means planning protein deliberately, because appetite won't remind you.
Source: News-Medical; Nutrients 2026
Earlier this fall
Nov 2, 2026 · Conference abstract (preliminary)
What it found: Among more than 250,000 adults with prediabetes and obesity, those on a GLP-1 were about 1.5 times more likely to bring blood sugar back to normal than those on metformin, with lower rates of heart attack and stroke. Presented at the American Heart Association's Scientific Sessions.
What it means for you: Promising, but it is an observational abstract, not yet peer reviewed. If you have prediabetes, it's a reasonable question to raise with your doctor, not a settled answer.
Source: American Heart Association newsroom, 2 Nov 2026
Nov 2, 2026 · Large observational study
What it found: In 59,269 UK Biobank adults, a higher share of body weight as fat-free mass tracked with less metabolic syndrome, while a higher total did not.
What it means for you: On a GLP-1, the goal is keeping the lean share high as weight comes off: protein first and resistance training. Our explainer.
Source: J Clin Endocrinol Metab 2026, doi:10.1210/clinem/dgag407
Oct 2026 · Professional guidance
What it found: The American College of Obstetricians and Gynecologists advised against GLP-1 use during pregnancy and recommended stopping one to two months before conception.
What it means for you: If pregnancy is possible, talk about contraception and timing with your prescriber. Tirzepatide can reduce how well birth-control pills work, so a non-oral method may be advised.
Source: Becker’s Hospital Review summary of the ACOG practice advisory
Sep 29, 2026 · Systematic review and meta-analysis
What it found: Across 10 studies covering more than 2.1 million pregnancies, including 8,325 exposed to a GLP-1 around conception, there was no clearly detectable increase in adverse outcomes for mothers or babies.
What it means for you: Reassuring if you found out you were pregnant while on one. The authors stress it does not show the drugs are safe to keep taking during pregnancy.
Source: The Pharmaceutical Journal; published in Med
Coming up
ObesityWeek, The Obesity Society's annual meeting, wraps up November 17 in National Harbor, Maryland. Results presented in its final days, and any full papers that follow, will be summarized here next week.
If you're on Medicare, open enrollment for 2027 Part D plans ends December 7. The plan you pick affects whether you can use Medicare's GLP-1 coverage: see current prices and Medicare details.
One short email a week: what was published, what kind of evidence it is, and whether it changes anything for you.
From Keep Everything Else, published by Habthera Nutrition. Sometimes we'll mention ASP-1, our protein supplement, and say so when we do. We never sell or share your address. Unsubscribe in one click. Who we are.
The week of November 16, 2026: a randomized trial in Nature Medicine found that resistance training three times a week during tirzepatide treatment cut lean tissue loss by 25% and raised strength about 10%; a Cleveland Clinic study presented at ObesityWeek found that people who stayed on or switched GLP-1s kept far more weight off over two years than those who stopped; and ObesityWeek abstracts reported that about a third of prior authorization requests for GLP-1s for weight loss are denied and that most people stay on lower doses than the label's step-up schedule.
We include new randomized trials, large observational studies, regulatory actions and major professional guidance relevant to people taking GLP-1 medicines, and label each by type of evidence so you can weigh it.
Keep reading